BlackRock Inc. Takes $15.50 Billion Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• BlackRock acquired 30.9 million Thermo Fisher shares worth approximately $15.5 billion, giving it an 8.36% stake. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with Thermo Fisher carrying a consensus “Moderate Buy” rating and an average price target of $619.41.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue up 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share.

BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,919,632 shares of the medical research company's stock, valued at approximately $15,501,867,000. BlackRock Inc. owned approximately 8.36% of Thermo Fisher Scientific as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of TMO. Pallas Capital Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $5,197,000. Deutsche Bank AG purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $609,053,000. Perigon Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $13,385,000. Commerzbank Aktiengesellschaft FI purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $32,967,000. Finally, Trust Co. of Vermont acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $25,326,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 price target on the stock. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. Piper Sandler increased their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Finally, Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Up 0.8%

Shares of NYSE:TMO opened at $590.00 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market cap of $218.15 billion, a P/E ratio of 31.74, a P/E/G ratio of 2.39 and a beta of 0.84. The stock's 50-day moving average is $533.64 and its 200-day moving average is $508.36.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter last year, the firm posted $4.28 EPS. The company's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Lisa P. Britt sold 5,850 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the sale, the vice president owned 14,784 shares of the company's stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 52,053 shares of company stock worth $30,643,589. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source